U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis

Bristol Myers Wins FDA Approval for Sotyktu for Psoriatic Arthritis Bristol Myers Wins FDA Approval for Sotyktu for Psoriatic Arthritis - Bristol-Myers Squibb (NYSE:BMY)

Bristol Myers won FDA approval for Sotyktu in active psoriatic arthritis, expanding its oral immunology franchise despite a slight after-hours stock dip.

U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis

Significantly more patients treated with once-daily, oral Sotyktu achieved an ACR20 response compared with placebo at

FDA Approves Deucravacitinib as First TYK2 Inhibitor for PsA

In clinical trials, more than half of all patients treated with deucravacitinib achieved at least 20% improvement in American College of Rheumatology response criteria.

U.S. FDA Approves Bristol Myers Squibb's Sotyktu ® (deucravacitinib ...